On January 11th, local time, Thomas Glanzmann, CEO of Carrefour, said in a conference call with investors, "We will fulfill our commitments for 2023, including completing transactions in China, and expect to report very solid performance that meets the latest guidelines." The company's CEO, Raimon Grifols, stated during the conference that "selling 20% of Shanghai Laishi's shares for approximately $1.8 billion will help us reduce debt, accelerate deleveraging, and achieve this year's goals." Raimon Grifols said that Carrefour expects to complete the sale of its Shanghai Laishi stake in Haier Group in the first half of 2024.
On the evening of December 29, 2023, Shanghai Laishi (002252. SZ) announced that Haier Group had reached a strategic cooperation agreement with medical and health enterprises and plasma product manufacturers, Kelifu. Haier Group will acquire 20% of the shares of Shanghai Laishi Blood Products Co., Ltd. held by Kelifu for a total price of 12.5 billion yuan and obtain a total of 26.58% of the voting rights. Based on this, the transfer price per share of Shanghai Laishi is calculated to be 9.405 yuan. The transaction is expected to be completed in the first half of 2024. After the completion of the transaction, Haier Group will become the actual controller of Shanghai Laishi, and Kelifu will continue to hold 6.58% of Shanghai Laishi's shares and retain a seat on the board of directors.